Aurinia Pharmaceuticals Inc (AUPH)

[Whalatane]

Thx for the link
Re OM CMS ( Medicare / Medicaid ) is definitely pushing for more at home dialysis. OM's Tablo system is an improvement over the NxStage system ....but costs $84,000...!!!
CMS likes it as it promotes adherence to at home use .
OM is still losing $ I think and am not sure on how much CMS will pay to cover use of this system .

OM was still losing money but they have a lot of cash on hand

Total cash, including restricted cash, cash equivalents and short-term investments, was $372.8 million as of December 31, 2021.

SWAV ...which I have owned since $40 a share ...is a major leap forward in treating calcified arteries and thus enabling better stent deployment during a PCI. Their IVL system is rapidly gaining use in the US , UK and EU and I think will be approved for use in Japan within a yr...

They have come out with a new catheter upgrade and can now also treat below the knee calcified arteries to enable better blood flow to the feet and drastically reduce the number of toe / foot surgeries many diabetics endured because of insufficient blood flow to these areas.

In elderly it is now often used instead of CABG ( bypass surgery ) .
CMS has dramatically increased the payments they make for these procedures .
The only negative this Qt was Omicron in Jan which delayed some treatments .
Co is cash flow positive I believe and like AUPH was subject to takeover spec this year .

AUPH ...as I've stated previously. There are some Nephrologists that like Lupkynis for its fast onset of action and that they can taper steroid use fairly fast . Patients hate the steroids .
Problem is the cost ...$92,000 a yr before discounts and rebates . Because of the cost most insurers carry it at a high tier which makes the copay unaffordable to most .

AUPH could cut their asking price significantly ( apparently this is not an expensive drug to make ) and make $ thru higher volume ....but so far have apparently chosen not to follow that path

Kiwi